Digital self-management package for people with interstitial lung disease
Official title: A Randomised Clinical Trial of a Digital Self-management Package for People With Interstitial Lung Disease
Run by University of Sydney · NCT06122233 · Data updated 2026-11-12
This study is testing a new smartphone app designed to help people with interstitial lung disease manage their health better and feel improved overall compared to standard care.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 400 (estimated) |
| Sponsor | University of Sydney Academic / other |
| Locations | 4 sites (Sydney, New South Wales and 3 other locations) |
| Status | Recruiting |
| Started | June 3, 2024 |
| Main results expected | June 2027 |
| Study ends | August 2027 |
| Registry record updated | April 4, 2025 |
| Trial ID | NCT06122233 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals diagnosed with fibrotic interstitial lung disease who possess a smartphone and have adequate digital literacy.
✕Probably not a fit
Patients who do not own a smartphone or lack the necessary digital literacy may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial compares a digital self-management package called REBUILD-SM, which includes a smartphone app, to standard care for individuals with interstitial lung disease (ILD). Participants in the intervention group will receive support from healthcare professionals while tracking their health data and completing questionnaires through the app. The study aims to evaluate improvements in health-related quality of life, symptoms, anxiety, self-efficacy, and physical activity over time. The control group will use a limited version of the app without the full self-management support.
Why it matters
Potential benefit: If successful, this approach could significantly enhance the quality of life and self-management capabilities for patients with interstitial lung disease.
How similar studies have gone: Other studies have shown promise in using digital health interventions for chronic disease management, suggesting potential success for this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of fibrotic ILD * In possession of a smartphone/tablet and an email address * Able to understand written and spoken English * Adequate digital literacy to complete requirements of trial * On stable ILD treatment for 30 days prior to enrolment Exclusion Criteria: * Not in possession of a smartphone/tablet * Insufficient digital literacy to complete requirements of trial * Unable to communicate in written/spoken English * Not on stable ILD treatment for 30 days prior to enrolment * Acute exacerbation within 30 days prior to enrolment * Participating in pulmonary rehab at enrolment or during 12-week intervention period * Unable to provide informed consent
Where it's running
-
Royal Prince Alfred Hospital
Sydney, New South Wales, Australia Recruiting -
The Prince Charles Hospital
Brisbane, Queensland, Australia Recruiting -
Alfred Hospital
Melbourne, Victoria, Australia Recruiting -
Austin Health
Melbourne, Victoria, Australia Recruiting
Study contacts
- Principal investigator: Tamera Corte — University of Sydney
- Study coordinator: Carly Barton
- Email: Carly.Barton@Sydney.edu.au
- Phone: +61 2 9515 5682
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
European database and biobank for childhood interstitial lung diseases
This study is creating a database and biobank to collect information and samples from children with interstitial lung diseases across Europe to improve their treatment and understanding of these conditions.
-
AccuPulmo CT Portal for Detecting Pulmonary Fibrosis on Chest CT
This study tests how well the AccuPulmo CT Portal can identify pulmonary fibrosis on existing chest CT scans from adults at Taichung Veterans General Hospital.
-
Advanced imaging to see how immunosuppression affects lung fibrosis activity
This trial will test whether immunosuppression changes PET and MRI measurements of active collagen deposition and tissue injury in people with non‑IPF interstitial lung disease who are starting treatment.
-
TX000045 for pulmonary hypertension from interstitial lung disease
This study tests TX000045 to see if it can reduce pulmonary vascular resistance in people with PH caused by interstitial lung disease and to check its safety.
-
68Ga-NI-FAPI-04 PET/CT imaging to detect fibroblast activation in cancer, fibrotic, and heart diseases
This test will see if an injected PET tracer called 68Ga-NI-FAPI-04 can better show fibroblast activation in people with tumors, pulmonary fibrosis, certain autoimmune vascular diseases, hypertrophic cardiomyopathy, or other cardiovascular conditions.
-
Nebulized human amniotic fluid for interstitial lung disease
This pilot will try nebulized diluted human amniotic fluid (HAF‑Matrix) in adults 40–90 with interstitial lung disease to check safety and look for early signs of benefit.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.